New Website for Cancer Pain Patients

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

After treatment with an aromatase inhibitor plus a CDK4/6 inhibitor, switching to camizestrant plus a CDK4/6 inhibitor showed a PFS benefit over remaining on the aromatase inhibitor.

Marwan G. Fakih, MD

February 24th 2025

New Partnership May Expand Use of Prostate Cancer AI Technology Platform

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Prior data support the ability of PATHOMIQ_PRAD to predict patients at a high risk of biochemical recurrence and metastasis.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Prior data support the ability of PATHOMIQ_PRAD to predict patients at a high risk of biochemical recurrence and metastasis.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

February 17th 2025

Surgery Trends Towards Improved Outcomes Vs SABR in Elderly NSCLC Group

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Factors such as World Health Organization status appeared to correlate with early mortality in an elderly non–small cell lung cancer cohort.

FDA Grants Priority Review to TLX250-CDx in Clear Cell RCC Imaging

Factors such as World Health Organization status appeared to correlate with early mortality in an elderly non–small cell lung cancer cohort.

Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.

February 26th 2025

Switching to Camizestrant/CDK4/6i Improved PFS in HR+/HER2– Breast Cancer

Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.

Related Content

Tim Cortese

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

After treatment with an aromatase inhibitor plus a CDK4/6 inhibitor, switching to camizestrant plus a CDK4/6 inhibitor showed a PFS benefit over remaining on the aromatase inhibitor.

Marwan G. Fakih, MD

February 24th 2025

New Partnership May Expand Use of Prostate Cancer AI Technology Platform

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Prior data support the ability of PATHOMIQ_PRAD to predict patients at a high risk of biochemical recurrence and metastasis.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

February 17th 2025

Surgery Trends Towards Improved Outcomes Vs SABR in Elderly NSCLC Group

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

FDA Grants Priority Review to TLX250-CDx in Clear Cell RCC Imaging

Factors such as World Health Organization status appeared to correlate with early mortality in an elderly non–small cell lung cancer cohort.

February 26th 2025